Skip to main content
. 2021 Feb 17;49:15. doi: 10.1186/s41182-021-00304-4

Table 1.

Clinical profile, investigations, and outcomes

Parameter N = 72
 Age in months 60 (36, 96)
 Boys, n (%) 45 (62.5)
 Weight in kg 16.0 (11.4, 20.75)
 Weight in Z score − 1.37 (− 2.18, − 0.24)
 PRISM III 8 (5, 12)
 Duration of illness in days 7 (5, 10)
Clinical features
 Fever, n (%) 72 (100)
 Edema, n (%) 35 (48.6)
 Fast breathing, n (%) 27 (37.5)
 Abdominal pain, n (%) 25 (34.7)
 Bleeding manifestations, n (%) 17 (23.6)
 Altered sensorium, n (%) 16 (22.2)
 Seizures, n (%) 16 (22.2)
 Headache, n (%) 14 (19.4)
 Purpuric rash, n (%) 8 (11.1)
 Oliguria, n (%) 6 (8.3)
 Hepatomegaly, n (%) 66 (91.7)
 Splenomegaly, n (%) 43 (59.7)
 Eschar, n (%) 14 (19.4)
Investigations
 Hemoglobin, g/dl 8.7 (7.4, 10.2)
 Platelet count, cells/mm3 44,000 (18,000, 80,000)
 Total bilirubin, mg/dl 0.8 (0.6, 1.9)
 Aspartate transaminase, U/L 185 (94, 285)
 Alanine transaminase, U/L 79 (49, 125)
 International normalized ratio 1.2 (1.0, 1.5)
Treatment
 Doxycycline, n (%) 65 (90.3)
 Azithromycin, n (%) 7 (9.7)
 IvIg only, n (%) 2 (2.8)
 IvIg with steroid, n (%) 2 (2.8)
Outcome
 Survivors, n (%) 60 (83.3)
 Length of PICU stay, days 5 (4, 9)
 Length of hospital stay, days 5 (3, 8)

All values expressed as median (IQR)

PRISM Pediatric Risk of Mortality